Role of Allogeneic Stem Cell Transplant in the Treatment of Primary Myelofibrosis

Basit Öğe Kaydı
dc.contributor.authorSoyer, Nur
dc.contributor.authorCelik, Ferit
dc.contributor.authorTombuloglu, Murat
dc.contributor.authorSahin, Fahri
dc.contributor.authorSaydam, Güray
dc.contributor.authorVural, Filiz
dc.date.accessioned2019-10-27T09:46:20Z
dc.date.available2019-10-27T09:46:20Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: The only known curative therapy for primary myelofibrosis is allogeneic hematopoietic stem cell transplant. Materials and Methods: We retrospectively evaluated 11 transplant procedures involving 10 patients (5 men and 5 women) diagnosed with primary myelofibrosis between 2005 and 2014. Results: The median age at the time of transplant was 60.5 years (range, 22-62 years). Stem cell sources were unrelated (n = 1) and related (n = 11) peripheral blood stem cells. Conditioning regimen was myeloablative for 8 and reduced intensity for 3 transplants. The median number of infused CD34+ cells was 6.8 x 10(6) cells/kg (range, 3.2-10.4 x 10(6) cells/kg). Neutrophil and platelet engraftment occurred at median of 22 days (range, 12-31 days) and 19.5 days (range, 13-56 days). Acute and chronic graft-versus-host disease was seen in 4 of 11 allografts. Relapse and nonrelapse mortality rates were 20%. Six patients (60%) were still alive without disease after median follow-up of 68.5 months (range, 17-120 months). Median progression-free survival and overall survival were 61 months (range, 2-120 months) and 65 months (range, 2-120 months). Conclusions: Our results suggest that allogeneic hematopoietic stem cell transplant may provide a curative treatment for primary myelofibrosis patients. A myeloablative regimen seems to be effective and safe, especially for younger primary myelofibrosis patients.en_US
dc.identifier.doi10.6002/ect.2016.0007
dc.identifier.endpage96en_US
dc.identifier.issn1304-0855
dc.identifier.issn1304-0855en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage93en_US
dc.identifier.urihttps://doi.org/10.6002/ect.2016.0007
dc.identifier.urihttps://hdl.handle.net/11454/29262
dc.identifier.volume17en_US
dc.identifier.wosWOS:000462169400016en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBaskent Univen_US
dc.relation.ispartofExperimental and Clinical Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConditioning regimenen_US
dc.subjectGraft-versus-host diseaseen_US
dc.subjectSurvivalen_US
dc.titleRole of Allogeneic Stem Cell Transplant in the Treatment of Primary Myelofibrosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu